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A B S T R A C T
Background: Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin
type 9, given every 2 weeks (Q2W), significantly reduced low-density lipoprotein cholesterol (LDL-C)
levels in Japanese hypercholesterolemic patients on background statin. We evaluated alirocumab 150 mg
every 4 weeks (Q4W) in patients on lowest-dose statin or non-statin lipid-lowering therapy (LLT).
Methods: ODYSSEY NIPPON was a double-blind study conducted in Japanese patients with LDL-C
100 mg/dL (heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia with
coronary heart disease) or 120 mg/dL (non-familial hypercholesterolemia, Japan Atherosclerosis
Society category III) on atorvastatin 5 mg/day or non-statin LLT. Patients were randomized (1:1:1) to
subcutaneous alirocumab 150 mg Q4W, alirocumab 150 mg Q2W, or placebo for the 12-week double-
blind treatment period (DBTP), followed by a 52-week open-label treatment period (OLTP). At entry
into the OLTP, patients received alirocumab 150 mg Q4W, with possible up-titration to 150 mg Q2W at
Week 24.
Results: Least-square mean percent change in LDL-C from baseline at Week 12 (primary efficacy
endpoint) was 43.8% for alirocumab Q4W, 70.1% for Q2W, and 4.3% for placebo. During the OLTP,
mean LDL-C change from baseline was 45.1% at Week 20, with a further reduction at Week 36, with
achieved levels maintained to Week 64. Percent of patients with 1 adverse event (DBTP) was 51.9% with
alirocumab Q4W, 47.2% with Q2W, and 46.4% with placebo. Most common adverse events were infections
and infestations (25.9%, 22.6%, 17.9%, respectively), gastrointestinal disorders (13.0%, 9.4%, 12.5%),
nervous system disorders (5.6%, 7.5%, 10.7%), and general disorders and administration-site conditions
(3.7%, 11.3%, 5.4%).
Conclusions: Hypercholesterolemic Japanese patients who tolerate only lowest-strength dose statin or
non-statin LLT can achieve robust LDL-C reduction with alirocumab 150 mg Q4W, in addition to their
current LLT. Alirocumab 150 mg Q4W dosing was efficacious and generally well tolerated without new
safety concerns.
(ClinicalTrials.gov number: NCT02584504)
© 2018 The Authors. ISDN. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cardiovascular disease (CVD) is the second most common cause
of death in Japan [1]. Whereas mean serum cholesterol levels are
decreasing in some countries, they are rising in Japan [2]. Reduction
of elevated low-density lipoprotein cholesterol (LDL-C) – one of the
most important modifiable risk factors for CVD [3] – is therefore
essential in Japan.
The clinical response to statins is more sensitive in Asian than in
Westernpopulations, leading to lower-approved dosage strengths in
Japan [4–7]. A sizable proportion of treated high-risk Japanese
patients do not, however, achieve the recommended LDL-C goals [8–
11]. In an analysis based on the Japanese Medical Data Vision
database in 33,325 high cardiovascular risk patients, 45% of whom
were receiving lipid-lowering therapy (LLT; 42% with a statin), 58% of
patients with a recent acute coronary syndrome or other coronary
heart disease achieved the Japan Atherosclerosis Society (JAS)
guideline-recommended LDL-C target of <100 mg/dL [8]; only 1% of
the patients on LLT were on a high-intensity statin and the use of
combination therapy was low. Reasons for not using the higher dose
of a statin or combination LLT include patient intolerance to these
medications and physician preference. An alternative approach to
lipid lowering is therefore necessary in patients who are unable to
tolerate statins and are not adequately controlled with non-statin
LLTs or the lowest-strength dose of statins.
Alirocumab is a highly specific, fully human monoclonal
antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9).
Alirocumab gained manufacturing and marketing approval in
Japan in June 2016 [12]. Alirocumab at doses of 75 mg or 150 mg
every 2 weeks (Q2W) reduces LDL-C levels by 44–72% in patients
with hypercholesterolemia with or without statin background
treatment [13–22]. Alirocumab 150 mg every 4 weeks (Q4W) was
identified, in a study conducted outside Japan [23], as a potential
dosing regimen in patients with hypercholesterolemia who did not
receive statin treatment. The combination of statin plus alirocu-
mab Q2W led to persistent reductions in LDL-C over the dosing
interval [14,15,18,21], but these reductions were not fully sustained
when alirocumab was given Q4W [13,15]. Statin treatment
increases free PCSK9 concentrations [24], resulting in higher
target-mediated clearance of alirocumab and a reduced duration of
effect [25]. Ezetimibe and fenofibrate also appear to increase free
PCSK9 concentrations, but the effect is much smaller [25], making
the Q4W regimen a feasible option as monotherapy and in patients
on non-statin LLT.
The aim of the ODYSSEY NIPPON study [26] was to explore the
alirocumab 150 mg Q4W regimen in Japanese patients with
hypercholesterolemia who are on the lowest-strength dose of
atorvastatin (5 mg/day) or are receiving a non-statin LLT (including
diet-therapy alone). The primary objective was to demonstrate the
reduction of LDL-C level by alirocumab 150 mg Q4W, or 150 mg
Q2W, vs. placebo after 12 weeks of treatment. The secondary
objectives were to determine the effect of alirocumab on other
lipid variables, the safety and tolerability of alirocumab, and the
long-term safety in patients receiving open-label alirocumab.
Methods
ODYSSEY NIPPON was a randomized, double-blind, placebo-
controlled, parallel-group phase 3 study conducted in 163 patients
recruited at 30 active sites in Japan. The first patient was enrolled
in November 2015 and the last patient was enrolled in October
2016 (http://clinicaltrials.gov/NCT02584504).
The study methods have been published [26]. Eligible patients
(age 20 years) had heterozygous familial hypercholesterolemia
(heFH) or non-familial hypercholesterolemia (non-FH), were onthe lowest-strength dose of atorvastatin (5 mg/day) or were
receiving a non-statin therapy (fenofibrate, bezafibrate, ezetimibe,
or diet-therapy alone), and had not achieved recommended LDL-C
levels according to the JAS guidelines [27]. Patients also had one or
more documented reason to explain why statin therapy was not
appropriate or why the lowest strength of statin dose could not be
increased. All patients with heFH (diagnosed by genotyping or
clinical criteria [28,29]) were eligible. Patients with non-FH were
to have a history of documented coronary heart disease, or a
history of diseases or other risk factors classified by the JAS as
primary prevention category III (i.e. ischemic stroke, peripheral
artery disease, diabetes mellitus, or chronic kidney disease) [27].
The study was performed according to the 18th World Medical
Assembly and all applicable amendments laid down by the World
Medical Assemblies, and the International Conference on Harmo-
nization guidelines for good clinical practice, all applicable laws,
rules, and regulations. The protocol was approved by the
institutional review boards of participating centers. All patients
provided written informed consent.
Intervention
The study consisted of a run-in period of 4 weeks, a screening
period of up to 3 weeks, a double-blind treatment period (DBTP) of
12 weeks, and an open-label treatment period (OLTP) of 52 weeks.
During the DBTP, patients were randomized, with a 1:1:1
allocation ratio, to receive alirocumab subcutaneously (SC)
150 mg Q4W (alternating with placebo to maintain the blind),
alirocumab 150 mg SC Q2W, or placebo SC for alirocumab Q2W.
Patients were stratified according to background statin (presence
or absence); patients who were not on statins were further
stratified by background fibrate/ezetimibe therapy or diet-therapy
alone. From Week 12 onwards (OLTP), all patients received
alirocumab 150 mg SC Q4W, with up-titration at Week 24 to
alirocumab 150 mg Q2W for patients not reaching the LDL-C goal
at Week 20. Open-label injections could be administered by
patients/designated persons at their home.
Key study endpoints and assessments
The primary efficacy endpoint was the percentage change in
calculated LDL-C from baseline to Week 12 using all LDL-C
measurements, regardless of adherence to treatment [intention-
to-treat (ITT) analysis]. Key secondary efficacy endpoints included
percentage change in calculated LDL-C from baseline to Week 12
(on-treatment analysis); percentage change in calculated LDL-C
from baseline to average Week 10–12 (ITT/on-treatment analysis);
percent change from baseline to Week 12 in apolipoprotein B (ITT/
on-treatment analysis), non-high-density lipoprotein cholesterol
(non-HDL-C) (ITT/on-treatment analysis), total cholesterol (ITT
analysis), lipoprotein(a) (ITT analysis), HDL-C (ITT analysis), fasting
triglycerides (ITT analysis), apolipoprotein A-1 (ITT analysis); and
the proportion of patients who reached the LDL-C goal at Week 12
(ITT/on-treatment analysis).
Safety and tolerability were assessed throughout the treatment
periods by analyzing adverse-event reports (including adjudicated
cardiovascular events), laboratory results, and vital signs. Labora-
tory analyses for all safety variables were performed by a central
laboratory, as detailed elsewhere [26].
Statistical analysis
The primary efficacy analysis population comprised the ITT
population (randomized population with an evaluable primary
efficacy endpoint). The on-treatment (modified ITT) population
Table 1
Baseline characteristics (randomized patients).
Characteristic Alirocumab 150 mg Q4W
(n = 54)
Alirocumab 150 mg Q2W
(n = 53)
Placebo Q2W
(n = 56)
Age, years, mean  SD 62.6  9.8 63.6  10.4 64.6  10.0
Men, n (%) 33 (61.1) 33 (62.3) 37 (66.1)
Body mass index (kg/m2), mean (SD) 25.8  3.9 26.4  4.7 25.6  4.0
Type of hypercholesterolemia, n (%)
Heterozygous FH 11 (20.4) 13 (24.5) 14 (25.0)
Non-FH 43 (79.6) 40 (75.5) 42 (75.0)
Cardiovascular history and risk factors, n (%)
Myocardial infarction 8 (14.8) 6 (11.3) 6 (10.7)
Unstable angina 1 (1.9) 11 (20.8) 4 (7.1)
Coronary revascularization procedure 9 (16.7) 16 (30.2) 13 (23.2)
Other clinically significant CHD 4 (7.4) 6 (11.3) 10 (17.9)
Ischemic stroke (excluding cardiogenic cerebroembolism) 1 (1.9) 5 (9.4) 1 (1.8)
Peripheral artery disease 0 0 1 (1.8)
Chronic kidney disease 6 (11.1) 10 (18.9) 9 (16.1)
Diabetes mellitus 30 (55.6) 32 (60.4) 28 (50.0)
Hypo HDL cholesterolemia 0 2 (3.8) 0
Family history of premature CAD 2 (3.7) 8 (15.1) 1 (1.8)
Impaired glucose tolerance 3 (5.6) 2 (3.8) 2 (3.6)
Lipid parameters, mean  SD or median (interquartile range)
LDL-C (Friedewald formula) (mg/dL) 154.2  59.5 149.2  31.1 149.4  32.6
Range 94:469 96:225 105:245
Apolipoprotein B (g/L) 126.2  41.6 123.4  20.2 123.9  20.5
Total cholesterol (mg/dL) 240.2  61.2 236.0  35.3 234.4  37.1
Non-HDL-C (mg/dL) 184.9  63.8 181.8  32.3 180.1 32.4
Lipoprotein (a) (mg/dL) 16.55 (7.70:34.80) 22.60 (10.70:44.80) 12.65 (8.45:23.05)
Triglycerides (fasted) (mg/dL) 140.5 (98.0:190.0) 159.0 (116.0:213.0) 150.5 (114.0:193.5)
HDL-C (mg/dL) 55.2 11.7 54.2 11.6 54.3 10.1
Background lipid-lowering therapy at randomization, n (%)
Statin therapy 19 (35.2) 18 (34.0) 19 (33.9)
Atorvastatin 5 mg/day 18 (33.3) 18 (34.0) 18 (32.1)
Atorvastatin 2.5 mg/day 1 (1.9) 0 1 (1.8)
Any LLT other than statins 26 (48.1) 26 (49.1) 27 (48.2)
Ezetimibe 7 (13.0) 14 (26.4) 11 (19.6)
Fibrate 19 (35.2) 12 (22.6) 16 (28.6)
Fenofibrate 9 (16.7) 4 (7.5) 6 (10.7)
Bezafibrate 10 (18.5) 8 (15.1) 10 (17.9)
Diet alone 9 (16.7) 9 (17.0) 10 (17.9)
CAD, coronary artery disease; CHD, coronary heart disease; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; LLT, lipid-lowering therapy; SD, standard deviation; Q2W, every 2 weeks; Q4W, every 4 weeks.
Fig. 1. LDL-C LS mean  SE over time (ITT population) in patients on alirocumab 150 mg Q4W, alirocumab 150 mg Q2W, or placebo Q2W. Arrows indicate administration of
study drug in each treatment group (pale-blue arrows indicate administration of placebo in the Q4W group). ITT, intention-to-treat; LDL-C, low-density lipoprotein
cholesterol; LS, least squares; SE, standard error; Q2W, every 2 weeks; Q4W, every 4 weeks.
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Table 2
Percent change from baseline to Week 12 in LDL-C, and from baseline to Week 12 (or averaged weeks 10–12 percent change) in secondary lipid variables.
Alirocumab
150mg Q4W
Alirocumab
150mg Q2W
Placebo Alirocumab 150mg Q4W vs. placebo Alirocumab 150mg Q2W vs. placebo
LS mean
differenceSE (%)
97.5% confidence
interval
p-value LS mean
difference SE (%)
97.5% confidence
interval
p-value
Primary endpoint: LDL-C (calculated)a
LS mean (SE) change from baseline (%) 43.82.2 70.12.3 4.32.2 39.53.1 46.5 to 32.4 <0.0001 65.83.1 72.9 to 58.7 <0.0001
Secondary lipid parameters, LS mean (SE) change from baseline (%)
LDL-Cb (Week 12) 43.42.1 70.12.2 2.82.1 40.63.0 47.4 to 33.8 <0.0001 67.43.0 74.2 to 60.5 <0.0001
LDL-Ca (Weeks 10–12) 54.21.9 69.91.9 3.71.9 50.52.7 56.6 to 44.5 <0.0001 66.22.7 72.3 to 60.1 <0.0001
LDL-Cb (Weeks 10–12) 54.01.9 69.91.9 2.61.9 51.42.6 57.4 to 45.4 <0.0001 67.32.7 73.3 to 61.3 <0.0001
Apolipoprotein Ba (Week 12) 32.22.0 57.92.0 6.02.0 26.22.8 32.5 to 19.9 <0.0001 51.92.8 58.3 to 45.5 <0.0001
Apolipoprotein Bb (Week 12) 31.82.0 58.02.0 4.61.9 27.22.8 33.5 to 20.9 <0.0001 53.42.8 59.7 to 47.1 <0.0001
Non-HDL-Ca (Week 12) 36.22.0 61.12.0 4.92.0 31.32.8 37.7 to 25.0 <0.0001 56.22.8 62.5 to 49.8 <0.0001
Non-HDL-Cb (Week 12) 35.91.9 61.12.0 3.51.9 32.42.7 38.6 to 26.3 <0.0001 57.62.7 63.8 to 51.4 <0.0001
Total cholesterola (Week 12) 25.81.5 44.71.6 3.31.5 22.52.2 27.4 to 17.6 <0.0001 41.42.2 46.4 to 36.5 <0.0001
Lipoprotein(a)a,c (Week 12) 31.73.3 49.63.3 1.33.3 32.94.6 43.4 to 22.5 <0.0001 50.94.7 61.5 to 40.3 <0.0001
HDL-Ca (Week 12) 7.71.8 9.91.8 2.01.8 5.72.5 0.0 to 11.3 0.0241 7.82.5 2.1 to 13.5 0.0022
Triglycerides (fasted)a,c (Week 12) 0.63.7 18.03.8 6.43.7 5.95.3 5.9 to 17.7 0.2645 11.65.3 23.5 to 0.4 0.0299
Apolipoprotein A-1a (Week 12) 6.81.6 9.11.7 2.91.6 3.92.3 1.2 to 9.0 0.0884d 6.22.3 1.0 to 11.4 0.0076d
HDL-C, high-density lipoprotein cholesterol; ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares; SE, standard error; Q2W, every 2 weeks; Q4W, every 4 weeks.
a ITT population.
b On-treatment population (modified ITT).
c Combined estimate obtained by combining adjusted means (SE) from robust regression model analyses of the different imputed datasets (multiple imputation).
d p-values provided for descriptive purposes.
T.
 Teram
oto
 et
 al.
 /
 Journal
 of
 Cardiology
 73
 (2019)
 218
–
227
 
221
Fig. 2. Secondary outcomes: percent change from baseline to Week 12: (A) ITT population; and (B) on-treatment (modified ITT) population. ap < 0.0001 vs. placebo;
bp < 0.025 vs. placebo (Bonferroni adjustment used to handle multiple comparisons). Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; ITT, intention-to-
treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares; TC, total cholesterol; TGs, triglycerides.
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double-blind injection and had an evaluable primary efficacy
endpoint during the efficacy DBTP. The safety population
comprised the randomized population who received at least one
dose of the study medication. The OLTP population comprised the
randomized population who received the open-label study
medication.
The primary efficacy endpoint was analyzed in the ITT
population using a mixed-effect model with repeated measures
(MMRM) approach. The model included the fixed categorical
effects of treatment group, time point (4, 8, 10, 12 weeks),
stratification factor of statin, treatment-by-time-point interaction
and statin-by-time-point interaction, and the continuous fixed
covariates of baseline calculated LDL-C value, and baseline value-
by-time-point interaction.
Continuous secondary endpoints with a normal distribution
were analyzed using the MMRM model. Continuous endpoints
with a non-normal distribution and binary secondary endpoints
were analyzed using a multiple imputation approach followed by
robust or logistic regression, respectively. Bonferroni adjustment
and a hierarchical procedure were used to handle multiplicity.The data for the safety analysis are reported descriptively. The
analysis was conducted in two steps. The first step concerned the
final efficacy and safety analyses, and was conducted when all
patients had been randomized and had at least all of their data up
to Week 24 (including 12 weeks DBTP and 12 weeks OLTP)
collected and validated. The second step was the final analysis of
the safety endpoints and exploratory efficacy assessment during
the OLTP, conducted at the end of the study with all data including
that from the OLTP.
The analysis was performed using SAS version 9.4 software (SAS
Institute Inc., Cary, NC, USA).
Results
Study population
Of 163 eligible patients, 54 were randomized to receive
alirocumab 150 mg Q4W group, 53 to receive alirocumab
150 mg Q2W, and 56 to receive placebo (Online Fig. 1). All
163 patients received the study treatment and were included in the
primary efficacy analyses and the adverse-event analysis at
Fig. 3. Percent change from baseline in calculated low-density lipoprotein cholesterol at Week 12 in the (A) 150 mg Q4W group and (B) 150 mg Q2W group (intention-to-treat
population), per randomization strata. CI, confidence interval; IRT, interactive response technology; LLT, lipid-lowering therapy; LS, least squares; Q2W, every 2 weeks; Q4W,
every 4 weeks.
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the DBTP, two (3.8%) in the alirocumab 150 mg Q2W group and one
(1.8%) in the placebo group. At Week 12, the primary efficacy
endpoint was missing for 1 patient (1.9%) in the alirocumab 150 mg
Q4W group, 2 patients (3.8%) in the alirocumab 150 mg Q2W
group, and 1 patient (1.8%) in the placebo group. These missing
values were accounted for by the MMRM model.
A total of 158 patients entered the 52-week OLTP, during which
all patients were started on alirocumab 150 mg Q4W with the
possibility of up-titration to Q2W at Week 24; 146 patients
completed the OLTP and were included in the long-term safety
analysis.
Patient baseline characteristics were well balanced across
treatment groups (Table 1). The mean  standard deviation (SD)
age of the study population was 63.6  10.1 years and 63.2% were
men.
Overall, 82.8% of patients had a history of CVD or cardiovascular
risk factors; 28.2% had a history of coronary heart disease, 23.3%
had heFH, 55.2% had diabetes mellitus, 15.3% had chronic kidney
disease, 4.3% had a history of ischemic stroke, and 0.6% had a
history of peripheral artery disease. The overall mean  SD
calculated LDL-C at baseline was 150.9  42.8 mg/dL
(3.91  1.11 mmol/L). The most common reasons pertaining to
low-dose statin treatment or prescription of non-statin LLT were a
history of statin-related side effects, treatment with medications
such as a CYP34A inhibitor and fibrates, and renal dysfunction
(Online Table 1).
Exposure to study drug injections during the DBTP was similar
across treatment groups, with a mean exposure of 11.9 weeks.Lipid and lipoprotein response
For the primary ITT efficacy analysis, least square (LS) mean -
 standard error (SE) percent changes in LDL-C concentration from
baseline to Week 12 were 43.8  2.2% in the alirocumab 150 mg
Q4W group and 4.3  2.2% in the placebo group, with a difference
between groups of–39.5% (97.5% CI 46.5 to–32.4; p < 0.0001)
(Fig. 1 and Table 2). The effect of alirocumab 150 mg Q4W was
consistent irrespective of stratification factor [statin presence: LS
mean difference 40.0% (97.5% CI 52.1 to 27.8); statin absence:
LS mean difference 39.2% (97.5% CI 48.0 to 30.4); interaction
p = 0.91]. LS mean (SE) percent change in LDL-C concentration from
baseline to Week 12 in the alirocumab 150 mg Q2W group was
70.1  2.3%, with a difference vs. placebo of 65.8% (97.5% CI
72.9 to 58.7; p < 0.0001) (Fig. 1 and Table 2). The effect of
alirocumab 150 mg Q2W was consistent irrespective of stratifica-
tion factor [statin presence: LS mean difference 66.9% (97.5% CI
79.1 to 54.6); statin absence: LS mean difference 65.2% (97.5%
CI 74.0 to 56.4; interaction p = 0.80)].
Percent change in calculated LDL-C from baseline to average
Week 10–12 was 54.2  1.9% for alirocumab 150 mg Q4W,
69.9  1.9% for alirocumab 150 mg Q2W, and 3.7  1.9% for
placebo in the ITT analysis. LS mean percent changes at Week 12 in
secondary efficacy endpoints are shown in Fig. 2 and
Table 2. Percent change from baseline in calculated LDL-C at
Week 12 was consistent across randomization strata (Fig. 3A and
B).
At Week 12, 85.2% of patients on alirocumab 150 mg Q4W and
96.2% on alirocumab 150 mg Q2W had achieved the LDL-C goal vs.
Fig. 4. Calculated LDL-C (mean  SE) over time in the (A) OLTP population and (B)
OLTP population according to up-titration status (OLTP). BL, baseline; LDL-C, low-
density lipoprotein cholesterol; OLTP, open-label treatment period; SE, standard
error; W, week.
T. Teramoto et al. / Journal of Cardiology 73 (2019) 218–22722414.3% on placebo (both p < 0.0001 vs. placebo) in the ITT analysis.
Similar results were observed in the on-treatment analysis (85.2%,
96.2%, and 10.8%, respectively; both p < 0.0001 vs. placebo).
Least-square mean percent change in LDL-C from baseline at
Week 12 in patients with coronary artery disease was 49.6% for
alirocumab Q4W, 67.9% for Q2W, and 0.3% for placebo.
Corresponding data for patients without coronary artery disease
are 42.3% for alirocumab Q4W, 71.1% for Q2W, and 6.4% for
placebo.
A mean  SD 45.1  21.6% LDL-C reduction was observed from
baseline to the first OLTP measurement (Week 20). The dose of
alirocumab was increased from 150 mg Q4W to 150 mg Q2W at
Week 24 in 35 patients (22.7%) resulting in a further LDL-C
reduction between Week 24 and Week 36. The reduction in LDL-C
was maintained over the course of the OLTP and the achieved
absolute LDL-C level was 71.3  42.1 mg/dL at Week 64
(Fig. 4A). Among patients not achieving the target LDL-C level at
Week 20, up-titration to 150 mg Q2W led to a substantial and
sustained reduction in LDL-C (Fig. 4B). Over three-quarters (76.9%)
of the patients on alirocumab 150 mg Q4W achieved the JAS LDL-Cgoal for very high-risk patients [27] at Week 20. The proportion of
patients who achieved the JAS LDL-C goal rose to 89.5% at Week 36,
after up-titration at Week 24 in those with hypercholesterolemia,
and was sustained through Week 64 (Online Fig. 2).
Safety
During the DBTP, 51.9% of patients on alirocumab 150 mg Q4W,
47.2% on alirocumab 150 mg Q2W, and 46.4% on placebo reported
the occurrence of an adverse event (Table 3). Four patients
reported a serious adverse event, one on alirocumab 150 mg Q4W,
two on alirocumab 150 mg Q2W, and one on placebo. One death
occurred, due to non-small-cell lung cancer (in the alirocumab
150 mg Q2W group), and was not considered related to the study
treatment; the only study-drug discontinuation during the DBTP
was in the patient who died.
The most common classes of adverse events during the DBTP
were infections and infestations (25.9% on alirocumab 150 mg
Q4W, 22.6% on alirocumab 150 mg Q2W, and 17.9% on placebo),
gastrointestinal disorders (13.0%, 9.4%, and 12.5%, respectively),
nervous system disorders (5.6%, 7.5%, and 10.7%, respectively), and
general disorders and administration site conditions (3.7%, 11.3%,
and 5.4%, respectively). The most common types of adverse events
(by preferred term level) were viral upper respiratory tract
infection (14.8% on alirocumab 150 mg Q4W, 15.1% on alirocumab
150 mg Q2W, and 16.1% on placebo), non-cardiac chest pain (0%,
7.5%, and 1.8%, respectively), fall (0%, 1.9%, and 5.4%, respectively),
dizziness (0%, 0%, and 5.4%, respectively), and pharyngitis (5.6%, 0%,
and 0%, respectively). Local injection site reactions were reported
in one patient (0.9%), in the alirocumab 150 mg Q4W group. There
was no relevant difference between treatment groups on safety
laboratory data during the DBTP (Table 3).
During the 52-week OLTP, 109 (69.0%) patients reported the
occurrence of any adverse event (Table 4). Twelve patients (7.6%)
reported a serious adverse event, none of which was fatal. Seven
patients (4.4%) had an adverse event that led to treatment
discontinuation. No new or unexpected safety findings emerged.
Discussion
In this study, hypercholesterolemic Japanese patients who were
not receiving statin therapy or who tolerate only the lowest-strength
dose of atorvastatin achieved clinically meaningful and statistically
significant reductions in LDL-C at Week 12 with alirocumab 150 mg
Q4W in addition to their existing LLT, including diet-therapy alone,
compared with patients receiving LLT plus placebo for alirocumab.
Most of the patients (85.2%) on the Q4W regimen achieved the JAS
LDL-C goal [27] at Week 12. With the alirocumab 150 mg Q2W
regimen, a reduction of 70.1% in LDL-C was achieved at Week 12, and
96.2% of patients achieved the JAS goal [27] for LDL-C. A consistent
reduction in LDL-C from baseline was observed from the first
measurement during the OLTP (Week 20), and decreased further at
Week 36, due to the possible dose adjustment to 150 mg Q2W, and
was maintained through Week 64. The alirocumab 150 mg Q4W and
Q2W dosing regimens were generally well tolerated during the 12-
week DBTP and the 52-week OLTP.
The reductions in LDL-C in this study are broadly consistent
with the phase 3 ODYSSEY JAPAN study [22], which reported a
62.5% reduction at Week 24 in LDL-C with alirocumab 75 mg
Q2W, with up-titration to 150 mg Q2W if Week 8 LDL-C was
100 mg/dL (heFH or non-FH with a history of coronary artery
disease) or 120 mg/dL (JAS category III). The reduction in LDL-C
was also sustained through Week 52 in ODYSSEY JAPAN. At Week
12, alirocumab treatment also resulted in beneficial reductions in
apolipoprotein B, non-HDL-C, total cholesterol, and lipoprotein
(a), and increases in HDL-C and apolipoprotein A-1. The
Table 3
TEAEs and laboratory variables (safety population) at 12 Weeks (DBTP).
Alirocumab 150 mg Q4W
(n = 54)
Alirocumab 150 mg Q2W
(n = 53)
Placebo Q2W
(n = 56)
Any TEAE, n (%) 28 (51.9) 25 (47.2) 26 (46.4)
Treatment-emergent SAE, n (%) 1 (1.9) 2 (3.8) 1 (1.8)
TEAE leading to death, n (%) 0 1 (1.9) 0
TEAE leading to treatment discontinuation during DBTP, n (%) 0 1 (1.9) 0
TEAE during DBTP leading to treatment discontinuation during open-label treatment period, n (%) 0 0 1 (1.8)
TEAEs (primary system organ class level) occurring in 5% of patients in any group, n (%)
Infections and infestations 14 (25.9) 12 (22.6) 10 (17.9)
Gastrointestinal disorders 7 (13.0) 5 (9.4) 7 (12.5)
Nervous system disorders 3 (5.6) 4 (7.5) 6 (10.7)
General disorders and administration site conditions 2 (3.7) 6 (11.3) 3 (5.4)
Musculoskeletal and connective tissue disorders 3 (5.6) 3 (5.7) 4 (7.1)
Injury, poisoning and procedural complications 0 3 (5.7) 5 (8.9)
TEAEs (preferred term level) in 5% of patients in any group, n (%)
Viral upper respiratory tract infection 8 (14.8) 8 (15.1) 9 (16.1)
Non-cardiac chest pain 0 4 (7.5) 1 (1.8)
Fall 0 1 (1.9) 3 (5.4)
Dizziness 0 0 3 (5.4)
Pharyngitis 3 (5.6) 0 0
Adjudicated cardiovascular event (any patient with treatment-emergent event), n (%)a 0 0 1 (1.8)
Laboratory parameters, n (%)
Alanine aminotransferase >3  ULN 0 0 0
Aspartate aminotransferase >3  ULN 0 0 0
Bilirubin >1.5  ULN 0 0 0
Creatine kinase >3  ULN 0 0 0
DBTP, double-blind treatment period; SAE, serious adverse event; TEAE, treatment-emergent adverse event; ULN, upper limit of normal; Q2W, every 2 weeks; Q4W, every
4 weeks.
a Ischemia-driven coronary revascularization procedure.
Table 4
TEAEs and laboratory variables during the 52-week OLTP (OLTP population).a
All patients (n = 158)
Any TEAE, n (%) 109 (69.0)
Treatment-emergent SAE, n (%) 12 (7.6)
TEAE leading to death, n (%) 0
TEAE leading to treatment discontinuation during open-label treatment period, n (%) 7 (4.4)
TEAEs (primary system organ class level) occurring in 5% of patients, n (%)
Infections and infestations 77 (48.7)
Gastrointestinal disorders 31 (19.6)
Musculoskeletal and connective tissue disorders 26 (16.5)
Skin and subcutaneous tissue disorders 19 (12.0)
Injury, poisoning and procedural complications 19 (12.0)
Metabolism and nutrition disorders 12 (7.6)
Nervous system disorders 11 (7.0)
General disorders and administration site conditions 9 (5.7)
Renal and urinary disorders 9 (5.7)
Respiratory, thoracic and mediastinal disorders 9 (5.7)
Investigations 8 (5.1)
Psychiatric disorders 8 (5.1)
TEAEs (preferred term level) occurring in 5% of patients, n (%)
Viral upper respiratory tract infection 54 (34.2)
Fall 11 (7.0)
Back pain 8 (5.1)
Adjudicated cardiovascular event (any patient with treatment-emergent event), n (%)b 1 (0.6)
Laboratory parameters, n (%)
Alanine aminotransferase >3  ULN 2/156 (1.3)
Aspartate aminotransferase >3  ULN 2/156 (1.3)
Bilirubin >1.5  ULN 0
Creatine kinase >3  ULN 4/156 (2.6)
OLTP, open-label treatment period; SAE, serious adverse event; TEAE, treatment-emergent adverse event; ULN, upper limit of normal.
a All patients received alirocumab 150 mg SC Q4W during the 52-week OLTP. At Week 24, a dose increase of alirocumab to 150 mg SC Q2W was automatically conducted
through the interactive web response system in patients with heterozygous familial hypercholesterolemia (heFH) or non-FH with documented coronary heart disease if
low-density lipoprotein cholesterol (LDL-C) was 100 mg/dL (2.59 mmol/L), and in non-FH category III patients if LDL-C was 120 mg/dL (3.10 mmol/L), at Week 20.
b Non-fatal myocardial infarction.
T. Teramoto et al. / Journal of Cardiology 73 (2019) 218–227 225alirocumab 150 mg Q4W regimen resulted in a 31.7% reduction in
lipoprotein(a), an independent predictor of coronary artery
disease [22,30–32].In our study, alirocumab was generally well tolerated, with no
apparent imbalance in adverse events across treatment groups
during the DBTP. Tolerability was maintained over the long term,
T. Teramoto et al. / Journal of Cardiology 73 (2019) 218–227226with the most frequent adverse events being viral upper
respiratory tract infection during the OLTP.
Drug response to statins differs in Asian vs. Western popula-
tions, with Asians achieving similar reductions in LDL-C as
Westerners at lower drug doses [4–7]. Body size appears to have
limited effect on drug efficacy [33,34], whereas genetic variability,
such as genetic polymorphism of metabolic enzymes or transpor-
ters, has a greater influence on the pharmacokinetic and
pharmacodynamic properties of drugs [5,35]. Owing to these
racial differences, lower statin treatment doses have been
approved in Japan [4–7]. However, several studies have shown
that a large proportion of high-risk Japanese patients do not
achieve the recommended LDL-C goals [8–10,31]. According to a
large study based on an electronic hospital-based claims database,
only 56% of patients with a recent acute coronary syndrome and
51% with other coronary heart disease met the JAS [27] LDL-C
target of <100 mg/dL. This failure was due in part to low rates of
use of high-intensity statin therapy and of combination therapy
[8]. The target population in ODYSSEY NIPPON was hypercholes-
terolemic Japanese patients who were on the lowest-strength dose
of atorvastatin or were receiving non-statin LLT, including diet-
therapy alone. In the prespecified analysis, regardless of the type of
background LLT, treatment with alirocumab (Q4W or Q2W) led to
substantial reductions in LDL-C across all subgroups.
The most frequent reason for not using a statin in this study, or
for using only low-dose statin, was a history of statin-related side
effects. Side effects from statin, particularly muscle symptoms
[36,37], limit many patients from achieving optimal LDL-C levels
[37–39]. The ODYSSEY CHOICE II study investigated alirocumab
150 mg SC Q4W (with possible up-titration to 150 mg Q2W at
Week 12) vs. placebo in patients with hypercholesterolemia while
receiving treatment with fenofibrate, ezetimibe, or diet-therapy
alone, most of whom had reported statin-associated muscle
symptoms. Alirocumab 150 mg Q4W (with up-titration to Q2W in
49.1% of patients) produced a 51.7% reduction in LDL-C from
baseline, 63.9% of patients achieved their LDL-C targets, and
alirocumab was generally well tolerated. On the basis of the data
from these studies, alirocumab 150 mg Q4W may offer a suitable
and effective clinical option in the management of Japanese
patients who are not receiving statin therapy or who tolerate only
the lowest-strength dose of atorvastatin.
Limitations
Study limitations include the 12-week DBTP. The dose of
atorvastatin used (5 mg/day) is more conservative than in
regions outside of Japan, limiting direct comparison of the results
between studies conducted in other countries or regions. The
putative effect of visit-to-visit variability in LDL-C levels on clinical
outcomes has not been established.
Conclusions
Hypercholesterolemic Japanese patients can achieve robust LDL-
C reductions with alirocumab 150 mg Q4W in addition to their prior
LLT, including atorvastatin 5 mg/day, fibrate, ezetimibe, ordiet alone.
Alirocumab 150 mg Q4W, with a possible dose increase to 150 mg
Q2W, offers an alternative, flexible dosing, and generally well-
tolerated lipid-lowering regimen for Japanese patients who are
unable to tolerate statins and are not adequately controlled with
non-statin LLTs or who are on the lowest-strength dose of statin.
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